BioSpace News Archive

Pfizer Inc. and OPKO Health, Inc. announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™, a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.

Glenn Boehnlein, Vice President, Chief Financial Officer, will represent the Company in a virtual presentation scheduled for 10:30 a.m. Eastern Time.

Bruno Villetelle, Global Head of Data and Digital in Novartis Global Drug Development, joins Seqster as they prepare for unprecedented growth and expansion.

Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2021 on Wednesday, Feb. 23 at 9 a.m., ET.

Rapid Medical today announced FDA breakthrough designation for its Comaneci™ embolization assist device to facilitate the treatment of cerebral vasospasm following hemorrhagic stroke.

Paper published in Nature Scientific Reports shows that Cofactor’s multianalyte biomarkers based on T cell subtype profiling (TCSP) predicted patient response to anti-PD-1 therapy in three different cancers (lung cancer, melanoma, and head and neck).

Radius Health, Inc. announced that it will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022.

Orphazyme A/S, a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, held an Extraordinary General Meeting, at which the general meeting:

Pharnext SA announces the appointment of Valérie Worrall as Chief Financial Officer, effective March 1st, 2022.

Kairos Pharma, Ltd. (“Kairos”), a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, today announced that it has received FDA approval to proceed with a Phase 2 clinical trial of ENV105 with apalutamide for the treatment of metastatic castration-resistant prostate cancer.